Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of iHIVARNA-01 in chronically HIV-infected patients on stable cART
2016-002724-83Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing iHIVARNA-01 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2016; status: completed.
02
Drugs
iHIVARNA-01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-002724-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002724-83.